Effects of fluvastatin on prothrombotic and fibrinolytic factors in type 2 diabetes mellitus.

Abstract

The effects of fluvastatin therapy on parameters of coagulation and fibrinolysis were evaluated in patients with diabetic dyslipidemia in a randomized, placebo-controlled study. Fluvastatin therapy was associated with a small reduction in factor VII coagulant activity, von Willebrand factor, and in plasminogen activator inhibitor 1 and tissue plasminogen activator antigens, but the effects of fluvastatin on hemostatic factors were much less marked than its effects on plasma lipids.

• Authors: K C Tan, E D Janus, K S Lam
• Journal: The American journal of cardiology (Am J Cardiol) Vol. 84 Issue 8 Pg. 934-7, A7 (Oct 15 1999) ISSN: 0002-9149 [Print] United States
• PMID: 10532516 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Anticholesteremic Agents
• Fatty Acids, Monounsaturated
• Indoles
• Lipids
• Fluvastatin

Topics

• Analysis of Variance
• Anticholesteremic Agents (pharmacology)
• Blood Coagulation (drug effects)
• Diabetes Mellitus, Type 2 (physiopathology)
• Double-Blind Method
• Fatty Acids, Monounsaturated (pharmacology)
• Female
• Fibrinolysis (drug effects)
• Fluvastatin
• Humans
• Hyperlipidemias (drug therapy)
• Indoles (pharmacology)
• Lipids (blood)
• Male
• Middle Aged